David T. Feinberg
David T. Feinberg's purchase track record
David T. Feinberg has only 1 open-market purchase with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 9/2/2022 | DEI | $508K | -14.4% | -26.6% | +3.1% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
Humana to drop 37 PPOs for 2027 Medicare Advantage plans. Humana announced it will discontinue 37 Preferred Provider Organization (PPO) plans for the 2027 Medicare Advantage enrollment period. The company noted that affected members may qualify for a Medigap open enrollment window without health questions. This structural change impacts the company's product lineup and member retention strategies for the upcoming year.
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 13, 2026
Piper Sandler cuts DEI price target to $11. Piper Sandler lowered its price target for Douglas Emmett to $11 while keeping a Neutral rating. This move aligns with the stock's current trading level near its support zone. Recent analysis also highlights concerns about the sustainability of the company's high dividend yield relative to its cash flow.
Transaction History
| EW | ▲ Buy | Grant | 3,251 | $0 | 5/8/2026 | View on chart |
| HUM | ▲ Buy | Grant | 766 | $0 | 1/2/2026 | View on chart |
| EW | ▲ Buy | Grant | 3,528 | $0 | 5/9/2025 | View on chart |
| EW | ▲ Buy | Grant | 2,308 | $0 | 7/10/2024 | View on chart |
| HUM | ▲ Buy | Option Exercise | 441 | $0 | 3/1/2023 | View on chart |
| DEI | ▲ Buy | Open Market | 25,000 | $508K | 9/2/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
EW: FDA Flags High-Risk Device Recall After Patient Death
The U.S. Food and Drug Administration flagged a potentially high-risk issue with Edwards Lifesciences' SAPIEN M3 delivery system, specifically the Commander M system, after a patient death was reported. The company has instructed customers to remove four specific lots of the device from use. This regulatory action highlights a significant safety concern for the company's key product line, drawing close regulatory scrutiny.
EW: FDA Flags High-Risk Device Recall After Patient Death. The U.S. Food and Drug Administration flagged a potentially high-risk issue with Edwards Lifesciences' SAPIEN M3 delivery system, specifically the Commander M system, after a patient death was reported. The company has instructed customers to remove four specific lots of the device from use. This regulatory action highlights a significant safety concern for the company's key product line, drawing close regulatory scrutiny.